WO2009029272A3 - Epitope vaccine for prevention and reversion of ad pathology - Google Patents

Epitope vaccine for prevention and reversion of ad pathology Download PDF

Info

Publication number
WO2009029272A3
WO2009029272A3 PCT/US2008/010186 US2008010186W WO2009029272A3 WO 2009029272 A3 WO2009029272 A3 WO 2009029272A3 US 2008010186 W US2008010186 W US 2008010186W WO 2009029272 A3 WO2009029272 A3 WO 2009029272A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell epitope
vaccines
reversion
pathology
prevention
Prior art date
Application number
PCT/US2008/010186
Other languages
French (fr)
Other versions
WO2009029272A2 (en
Inventor
Michael G. Agadjanyan
Anahit Ghochikyan
Original Assignee
Agadjanyan Michael G
Anahit Ghochikyan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agadjanyan Michael G, Anahit Ghochikyan filed Critical Agadjanyan Michael G
Priority to EA201170238A priority Critical patent/EA026787B1/en
Publication of WO2009029272A2 publication Critical patent/WO2009029272A2/en
Publication of WO2009029272A3 publication Critical patent/WO2009029272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Abstract

Vaccines for treating Alzheimer's disease (AD) comprising specific epitopes, including a self B cell epitope of amyloid peptide, a foreign T cell epitope derived from conventional vaccines or pathogens and a molecular adjuvant are disclosed. The approach uses a plurality of copies of the B cell epitope in vaccine composition to significantly enhance the anti-amyloid beta humoral immune response. Inclusion of various Th epitopes in the composition allows quick and potent induction of potent anti-amyloid beta antibody responses using pre-existing memory CD4+ Th cells induced in a general population by previous infections or immunizations with conventional vaccines.
PCT/US2008/010186 2007-08-27 2008-08-27 Epitope vaccine for prevention and reversion of ad pathology WO2009029272A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201170238A EA026787B1 (en) 2007-08-27 2008-08-27 Nucleic acid construct and use thereof in treating, preventing and inhibiting alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96621807P 2007-08-27 2007-08-27
US60/966,218 2007-08-27
US12427408P 2008-04-16 2008-04-16
US61/124,274 2008-04-16

Publications (2)

Publication Number Publication Date
WO2009029272A2 WO2009029272A2 (en) 2009-03-05
WO2009029272A3 true WO2009029272A3 (en) 2009-12-23

Family

ID=40388077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010186 WO2009029272A2 (en) 2007-08-27 2008-08-27 Epitope vaccine for prevention and reversion of ad pathology

Country Status (2)

Country Link
EA (1) EA026787B1 (en)
WO (1) WO2009029272A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
US20120014987A1 (en) * 2009-03-26 2012-01-19 Yoh Matsumoto Dna vaccine for alzheimer's disease
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
DE102011057019A1 (en) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard for the quantification of pathogenic aggregates from endogenous proteins
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN112165956A (en) * 2018-04-10 2021-01-01 Ac免疫有限公司 Anti-abeta therapeutic vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088548A1 (en) * 1999-12-08 2006-04-27 Benjamin Chain Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20060275264A1 (en) * 2005-05-31 2006-12-07 Helen Fitzsimons Novel glutamic acid decarboxylase (GAD) chimera and methods of use
US20070178117A1 (en) * 2005-11-29 2007-08-02 Marconi Richard T Polyvalent Chimeric OspC Vaccinogen and Diagnostic Antigen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9907855A (en) * 1998-02-12 2001-04-24 Immune Complex Corp Strategically modified hepatitis b core protein conjugate, protein particle, protein particle conjugate, immunogenic fusion protein conjugate, inoculum, and, process to induce antibodies in an animal host
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088548A1 (en) * 1999-12-08 2006-04-27 Benjamin Chain Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20060275264A1 (en) * 2005-05-31 2006-12-07 Helen Fitzsimons Novel glutamic acid decarboxylase (GAD) chimera and methods of use
US20070178117A1 (en) * 2005-11-29 2007-08-02 Marconi Richard T Polyvalent Chimeric OspC Vaccinogen and Diagnostic Antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GELINAS ET AL: "Immunotherapy for Alzheimer's disease", PNAS, vol. 101, no. 2, 2004, pages 14657 - 14662, XP002316961, DOI: doi:10.1073/pnas.0404866101 *

Also Published As

Publication number Publication date
EA026787B1 (en) 2017-05-31
EA201170238A1 (en) 2012-12-28
WO2009029272A2 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2009029272A3 (en) Epitope vaccine for prevention and reversion of ad pathology
Hegerle et al. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
RU2017104529A (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND WAYS OF THEIR APPLICATION
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
NO20071609L (en) Immunogenic composition for use in vaccination against staphylococci
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DOP2013000029A (en) PEPTIDIC ANTIBODIES BETA AMILOIDE ANTI-N3PGLU AND USES OF THE SAME
TW200722101A (en) Novel composition
WO2008030282A3 (en) Recombinant vaccine against bluetongue virus
WO2008068631A8 (en) Vaccines including antigen from four strains of influenza virus
MA32819B1 (en) VACCINE COMBINALLY COMBINED AGAINST ACELLULAR POULTRY
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
ES2597832T3 (en) Acellular vaccine against pertussis
JP2016106117A5 (en)
ATE522541T1 (en) BACTERIAL ADHESIN CONFORMERS
RU2014127714A (en) TOXIN VACCINE Clostridium difficile
WO2017044895A3 (en) MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
JP2011517938A5 (en)
Campuzano et al. A recombinant multivalent vaccine (rCpa1) induces protection for C57BL/6 and HLA transgenic mice against pulmonary infection with both species of coccidioides
PH12020551670A1 (en) Anti-abeta therapeutic vaccines
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2008097267A3 (en) Vaccines against vesicular stomatitis
WO2010080188A3 (en) Epitope targeted anthrax vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795660

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795660

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201170238

Country of ref document: EA